FDA narrows levothyroxine potency specs
Executive Summary
Levothyroxine sodium potency specifications are tightening in response to concerns that the drug's potency may deteriorate prior to its expiration date. Currently allowed up to 10 percent potency degradation over the course of the product's shelf life, the thyroid treatment will now be required to meet a 95 percent to 105 percent potency specification until the expiration date, consistent with the recommendations of a joint FDA advisory committee. Presented with FDA's analysis of stability data supplied by manufacturers, the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees overwhelmingly recommended that potency specifications should be narrowed (1"The Pink Sheet" Oct. 9, 2006, p. 16). Manufacturers will have two years to comply with the specifications, according to FDA...
You may also be interested in...
Tighter Levothyroxine Standards Are Only First Step To Higher Quality – Cmte.
Tightening levothyroxine potency standards will not address underlying concerns about the quality of the manufacturing process for such products, members of the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees said
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.